This GEMM has also been used to assess the in vivo impact of perifosine, an oral inhibitor of the AKT and RAS/MAPK pathways, both of which are known to be activated by the enhanced RTK signaling common in glioma (50). Here, AKT1 is linked to central nervous system cancer.